Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831830 | 1.00 | CA12 (0.68) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9535518 | 0.90 | NPSR1 (0.65) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL2005010 | 0.90 | CA12 (0.81) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11705580 | 0.85 | MEN1 (0.86) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9001311 | 0.85 | CA12 (0.72) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2136408 | 0.81 | CES1 (0.81) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11026205 | 0.81 | CA12 (0.68) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18395077 | 0.81 | CES1 (0.81) | ALDH1A1MAPTTDP1CYP2C9HTT | |
| SCHEMBL3367872 | 0.81 | MEN1 (0.73) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1592808 | 0.81 | MAPT (0.82) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427798-B2 | Heat-sensitive recording composition | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250001788-A1 | HEAT-SENSITIVE RECORDING COMPOSITION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4442467-A1 | THERMAL RECORDING COMPOSITION | Nippon Kayaku Kabushiki Kaisha (JP) | 2024-10-09 | — | — | EP | disclosed |
| EP-4442468-A1 | HEAT-SENSITIVE RECORDING COMPOSITION | Nippon Kayaku Kabushiki Kaisha (JP) | 2024-10-09 | — | — | EP | disclosed |
| US-20240326501-A1 | HEAT-SENSITIVE RECORDING COMPOSITION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | disclosed |
| WO-2023100900-A1 | THERMAL RECORDING COMPOSITION | 日本化薬株式会社 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023100902-A1 | HEAT-SENSITIVE RECORDING COMPOSITION | 日本化薬株式会社 | 2023-06-08 | — | — | WO | disclosed |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-100422182-C | Imidazopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-10-01 | — | — | CN | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| CN-1856495-A | Imidazopyridine Derivatives as Inducible NO-Synthase Inhibitors | ALTANA PHARMA AG (DE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | CA12 4714/4885CA1 3334/4885CA2 815/4885 |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | CA12 4714/4885CA1 3334/4885CA2 815/4885 |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | CA12 4714/4885CA1 3334/4885CA2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.